Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › BNTC
SILVERARC CAPITAL MANAGEMENT, LLC position in BNTC
BENITEC BIOPHARMA INC · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 443,109 shares of BNTC (BENITEC BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$4.4M, representing 0.56% of its reported portfolio and ranking #41 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed BNTC holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's BNTC position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in BNTC in Q1 2025 at 250,000 shares (US$3.3M). The position peaked in Q4 2025 at 731,717 shares, worth US$9.9M. Across 7 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 443,109 shares valued at US$4.4M — a reduction of -236,717 shares quarter over quarter.. Notable position changes include a 165% increase in Q4 2025 (shares fell 21% over the following quarter), a 35% trim in Q3 2026 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 250.00K | $3.25M | New |
| Q2 2025 | 253.23K | $2.96M | Add |
| Q3 2025 | 276.27K | $3.88M | Add |
| Q4 2025 | 731.72K | $9.86M | Add |
| Q1 2026 | 717.73K | $7.64M | Reduce |
| Q2 2026 | 679.83K | $9.10M | Reduce |
| Q3 2026 | 443.11K | $4.43M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BNTC and 13F data
BNTC (BENITEC BIOPHARMA INC) is a Health Care company. 52 other funds we track also report a position in BNTC — the largest reported positions include MONTANOVA CAPITAL, LLC (US$154.5M), Nantahala Capital Management, LLC (US$19.9M), INFINITUM ASSET MANAGEMENT, LLC (US$12.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BNTC
- MONTANOVA CAPITAL, LLC 11.55M sh · $154.52M · Q2 2026
- Nantahala Capital Management, LLC 1.49M sh · $19.91M · Q2 2026
- INFINITUM ASSET MANAGEMENT, LLC 923.01K sh · $12.35M · Q2 2026
- Simplify Asset Management Inc. 1.00M sh · $10.02M · Q3 2026
- MYDA Advisors LLC 250.00K sh · $3.35M · Q2 2026
- Lion Point Capital, LP 62.00K sh · $829.56K · Q2 2026
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held BNTC?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed BNTC holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in BNTC?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 443.11K shares of BNTC (BENITEC BIOPHARMA INC), valued at $4.43M, representing 0.56% of its reported portfolio and ranking #41.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling BNTC?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC reduced its position in BNTC. The position peaked in Q4 2025 at 731.72K shares.
Which other funds hold BNTC?
Other major institutional holders of BNTC include MONTANOVA CAPITAL, LLC, Nantahala Capital Management, LLC, INFINITUM ASSET MANAGEMENT, LLC, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.